Clinical trials: Sorafenib
- Drug or intervention Sorafenib
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Pharmacokinetics, Bioavailability
Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005…
- Trial name
- NCT05967377
- Testing
- Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005 Sorafenib Tablet A - Period 1
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Fasting
Bioequivalence Study of Sorafenib Tablet and Nexavar
Randomized, open-label, 3-way reference replicated crossover bioequivalence study of sorafenib 200 mg tablet and nexavar (reference) following a 200 mg dose in healthy subjects under fasting conditions.
- Trial name
- NCT02599337
- Testing
- Nexavar, Sorafenib
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yabao Pharmaceutical Group
Healthy, Male
Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics characteristics ,tolerability, and safety after orally administrating SYO-1644 to healthy male volunteers in randomized, active-controlled, open-label clinical study.
- Trial name
- NCT03674060
- Testing
- SYO-1644, Nexavar tab
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation
Drug Interactions
Sorafenib Drug Drug Interaction Study in Healthy Male Subjects
To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and elimination of sorafenib and safety in healthy male subjects
- Trial name
- NCT02332031
- Testing
- Sorafenib (Nexavar, BAY43-9006), Levothyroxine
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.
- Trial name
- NCT06797427
- Testing
- DPH001, Nexavar (Sorafenib)
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Disruptive Pharma
Biological Availability
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
The primary objective of the study is to Investigate the relative bioavailability of sorafenib as 400 mg (4 x 100 mg) tablet for oral suspension formulation in comparison to 400 mg (2 x 200 mg) marketed tablet formulation.
- Trial name
- NCT02538393
- Testing
- Sorafenib (BAY43-9006) Film-coated tablet, Sorafenib (BAY43-9006) Oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Liver Disease
Hepatic Impairment Study
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose.
- Trial name
- NCT00829231
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bayer